Table 3.
Distribution of low- and high-risk HLA alleles for HIV-1 superinfection in monoinfected subjects with continued sexual risk behavior and superinfected subjects.
| Contacts per Month Median (Range) | Infection Status | FU Months | HLA-A Allele 1 | HLA-A Allele 2 | HLA-B Allele 1 | HLA-B Allele 2 | HLA-C Allele 1 | HLA-C Allele 2 | HLA-DRB1 Allele 1 | HLA-DRB1 Allele 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0 (0 – 2) | MI | 45.1 | *03 | *03 | *07 | *07 | *07 | *07 | *07 | *15 |
| 0.5 (0 – 1) | MI | 32.4 | *02 | *23 | *44 | *50 | *05 | *06 | *04 | *04 |
| 1.0 (0– 30) | MI | 24.0 | *02 | *02 | *44 | *51 | *05 | *14 | *04 | *11 |
| 1.0 (1 – 4) | MI | 27.9 | *02 | *03 | *39 | *57 | *06 | *07 | *01 | *07 |
| 1.0 (0 – 2) | MI | 32.8 | *30 | *30 | *35 | *57 | *04 | *18 | *13 | *15 |
| 1.0 (1 – 2) | MI | 34.8 | *02 | *02 | *40 | *46 | *01 | *02 | *09 | *13 |
| 1.0 (1 – 1) | MI | 36.1 | *02 | *02 | *13 | *14 | *07 | *08 | *13 | *15 |
| 1.0 (0 – 1) | MI | 37.4 | *11 | *68 | *07 | *51 | *01 | *07 | *11 | *15 |
| 1.0 (0 – 10) | MI | 38.3 | *02 | *24 | *07 | *18 | *07 | *07 | *01 | *11 |
| 1.0 (1 – 2) | MI | 40.3 | *02 | *11 | *15 | *27 | *02 | *03 | *04 | *04 |
| 1.0 (0 – 15) | MI | 42.1 | *32 | *68 | *40 | *44 | *03 | *07 | *11 | *15 |
| 1.0 (0 – 5) | MI | 59.2 | *01 | *01 | *15 | *49 | *07 | *12 | *07 | *13 |
| 1.5 (1 – 2) | MI | 34.7 | *02 | *29 | *35 | *49 | *04 | *07 | *04 | *04 |
| 1.5 (0 – 20) | MI | 65.4 | *01 | *03 | *14 | *57 | *06 | *08 | *07 | *13 |
| 2.0 (0 – 4) | MI | 28.1 | *30 | *33 | *14 | *53 | *08 | *15 | *03 | *13 |
| 2.0 (1 – 5) | MI | 28.9 | *02 | *68 | *35 | *44 | *04 | *05 | *04 | *11 |
| 2.0 (1 – 4) | MI | 41.5 | *11 | *29 | *27 | *44 | *01 | *16 | *01 | *07 |
| 2.0 (0 – 5) | MI | 42.1 | *01 | *68 | *08 | *44 | *05 | *07 | *03 | *16 |
| 3.0 (2 – 4) | MI | 32.7 | *30 | *30 | *18 | *35 | *04 | *05 | *03 | *13 |
| 3.0 (1 – 5) | MI | 53.7 | *02 | *68 | *27 | *44 | *01 | *05 | *04 | *11 |
| 5.0 (0 – 50) | MI | 41.5 | *25 | *68 | *18 | *58 | *06 | *12 | *13 | *13 |
|
| ||||||||||
| 0.0 (0 – 1) | SI | 11.2 | *26 | *32 | *07 | *38 | *07 | *12 | *09 | *15 |
| 1.0(1 – 3) | SI | 19.9 | *01 | *68 | *35 | *57 | *07 | *07 | *04 | *07 |
| 1.0 (1 – 4) | SI | 21.1 | *24 | *31 | *35 | *51 | *04 | *15 | *04 | *07 |
| 2.01 | SI | 3.5 | *24 | *66 | *35 | *41 | *04 | *17 | *13 | *15 |
| 2.0(1 – 3) | SI | 16.9 | *02 | *29 | *44 | *44 | *05 | *16 | *01 | *07 |
| 4.01 | SI | 4.6 | *23 | *29 | *44 | *44 | *04 | *16 | *04 | *07 |
| 5.01 | SI | 3.8 | *01 | *03 | *08 | *35 | *04 | *07 | *01 | *03 |
| 6.5 (3 – 10) | SI | 10.9 | *02 | *68 | *35 | *40 | *03 | *04 | *08 | *16 |
| 8.01 | SI | 5.5 | *03 | *29 | *44 | *57 | *16 | *18 | *01 | *07 |
| NA | SI | 9.8 | *03 | *32 | *35 | *47 | *04 | *07 | *07 | *08 |
FU, follow-up; MI, monoinfection; NA, not available; SI, superinfection.
a
Only one data point available; blue, low-risk HLA allele; red, high-risk HLA allele. Contact numbers are median (range) values during the follow-up period.